View more in
Cancer

Gefitnib Delays Early Relapse, Fails to Improve DFS or OS Compared to Chemotherapy in EGFR-mutant NSCLC

targetedonc.com
 2021-06-06

Cover picture for the articleNew data from the phase 3 IMPACT trial shows the advantages and shortcomings of gefitinib in patients with EGFR-mutant non-small cell lung cancer. Early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer (NSCLC) was delayed with the adjuvant treatment of gefitinib (Iressa). Despite this outcome, the EGFR inhibitor did not significantly improve disease-free survival (DFS) or overall survival (OS) compared with cisplatin/vinorelbine, according to data from the phase 3 Japanese IMPACT trial (UMIN000006252) presented at the 2021 virtual ASCO Annual Meeting.1.

www.targetedonc.com

Comments / 0

Comments / 0